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Abstract 
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Patients are 
often diagnosed with advanced stage EOC which has a high chance of cancer 
recurrence and metastasis and thus with a poor survival rate. It remains a huge 
challenge to understand the cellular and molecular mechanisms of the aggressive 
behaviour of EOC cells. In this study we investigated the role of an 
immunomodulatory cytokine IL-33 and its receptor ST2 in mediating the growth and 
metastasis of EOC, and the association of their expression with disease prognosis. 
Our data show that both IL-33 and ST2 were highly up-regulated in EOC tumour 
tissues compared with normal ovary and ovarian benign tumours, and the expression 
levels were further increased in tumour tissues at the metastatic site compared with 
the primary site. The expression levels of IL-33 and ST2 were also positively 
correlated with the expression of Ki-67, and negatively correlated with the survival 
time of EOC patients. Using EOC cell lines, we observed that cells knocked down of 
IL-33 gene by siRNA had reduced migratory and invasive potential, while full length 
human IL-33 (fl-hIL-33) promoted the invasive, migratory and proliferative capacity of 
EOC cells and this process could be inhibited by IL-33 decoy receptor sST2. 
Signaling pathway analysis suggested that IL-33 increased the phosphorylation of 
ERK and JNK which was blocked by sST2. Fl-hIL-33-induced increases in EOC cell 
migration, invasive potential and proliferation were specifically abrogated by 
treatment with the ERK inhibitor U0126 while JNK inhibitor SP600125 only disrupted 
IL-33-induced enhancement of EOC cell viability. Taken together, our data suggest 
that IL-33/ST2 axis closely associates with poor prognosis of EOC patient survival 
time, and it promotes ovarian cancer growth and metastasis through regulating ERK 
and JNK signaling pathways. Thus IL-33 and/or ST2 might be potential prognosis 
markers and therapeutic targets for EOC patients. 
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Highlights: 
x Increased IL-33/ST2 expression in EOC tumours, particularly EOC metastatic 
tumours 
x Expression levels of IL-33/ST2 negatively correlate with patient survival time  
x Fl-hIL-33 promotes the invasive, migratory and proliferative capacity of EOC 
cells 
x Fl-hIL-33 promotes ECO growth and metastasis through ERK and JNK 
signaling pathways   
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1. Introduction 
Ovarian cancers are a group of heterogeneous, rapidly progressing gynaecological 
malignancies with high rate of mortality in women. Epithelial ovarian cancer (EOC) is 
the most lethal ovarian cancer accounting for 80 to 90% of all cases, with serous 
ovarian carcinoma as the most common and most aggressive subtype of EOC (Bell, 
2005; Kurian et al., 2005; Marquez et al., 2005). Despite recent advances in surgical 
resections and systemic chemotherapies, the prognosis of EOC remains poor and 
the 5-year survival rate is only approximately 30% after initial diagnosis (Armstrong, 
2002; Jemal et al., 2009; McGuire et al., 1996). The main reason for the poor survival 
rate is that currently there are no effective screening methods for early symptoms of 
EOC which are often silent. 70% of patients are first diagnosed with advanced stage 
of the disease with metastasis, which remains the leading cause of cancer relapse 
and ultimately death from EOC (Goff et al., 2000; Heintz et al., 2006; Stirling et al., 
2005). Thus there is an urgent need to investigate the molecular mechanisms 
associated with the aggressive growth and metastatic ability of ovarian cancer. 
 
IL-33 is a member of the IL-1 cytokine family, originally described as a nuclear protein 
in high endothelial venules (Baekkevold et al., 2003). IL-33 is expressed in many 
organs and cells (Schimitz et al., 2005), it induces synthesis of various chemokines 
and cytokines such as IL-5 and IL-13 via binding to its heterodimeric receptor ST2 
and IL-1R accessory protein (Liew, 2012). ST2 exists in two forms due to the 
alternative splicing: a transmembrane full-length form (ST2L) and a soluble, secreted 
form (sST2) acting as a decoy receptor (Oshikawa et al., 2002). ST2 is expressed by 
various immune cells including dendritic cells (DCs), Th2 cells, mast cells and natural 
killer (NK) cells (Lohning et al., 1998; Moritz et al., 1998; Xu et al., 1998), as well as 
tissue specific cells such as endothelial cells and decidual stromal cells (Hu et al., 
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2014; Zeyda et al., 2013).  
 
Since the discovery of IL-33 in 2005 (Schmitz et al., 2005), numerous studies have 
suggested that IL-33 plays diverse but important roles in immune mediated diseases 
such as infection, allergy and autoimmune diseases (Liew, 2012). Interestingly, a few 
recent studies in cancer indicate a potential role of IL-33 in modulating anti-tumour 
immunity and tumour growth. Elevated levels of IL-33 have been detected in the 
serum samples of gastric cancer (Sun et al., 2011), non-small cell lung cancer (Hu et 
al., 2013) and breast cancer patients (Liu et al., 2014), while the serum levels of sST2 
were reported to be associated with worse prognostic factors in hepatocellular 
(Bergis et al., 2013) and breast cancer (Lu et al., 2014), suggesting IL-33/ST2 
signaling pathway is likely to be involved in the development of a variety of cancers. 
However, the function of IL-33 in tumour progression is less clear. While transgenic 
expression of IL-33 in mice activated NK and CD8 T cells and inhibited tumour growth 
and metastasis in melanoma and lung carcinoma animal models (Gao k., et al., 2013; 
Gao X., et al., 2015), induced IL-33 expression enhanced the tumourigenic activity of 
rat glioma cells (Fang et al., 2014). In addition, the IL-33/ST2 axis promoted mouse 
mammary carcinoma growth and metastases by facilitating intratumoural 
accumulation of immunosuppressive cells (Jovanovic et al., 2011 and 2014). Thus 
despite convincing evidence suggesting a role for IL-33/ST2 in cancer growth and 
progression, its exact function and more importantly the underlying mechanisms in 
tumour development remain unclear. 
 
In this study we focused on the role of IL-33/ST2 in the development of EOC and 
examined the underlying mechanism of its function. We evaluated the correlation of 
the expression levels of IL-33 and ST2 in dissected tumour tissues with the survival 
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time of these EOC patients. Furthermore, we investigated the function of IL-33/ST2 
axis in EOC cell growth, migration and invasion and the important signaling pathways. 
To our knowledge, our study is the first to demonstrate that IL-33 and/or ST2 may be 
a potential prognosis markers for EOC patients, and IL-33/ST2 axis plays a key role 
in the control of EOC growth and metastasis. 
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2. Materials and methods 
2.1. Patients 
A total of 192 specimens were used for this study. 20 normal ovary tissues 
(hysterectomy specimens with non-ovarian disease), 20 benign ovarian tumours and 
152 EOC samples (88 serous cystadenocarcinoma tumours, 16 mucinous 
cystadenocarcinoma tumours, 3 endometrioid carcinoma tumours, 5 clear cell 
carcinoma tumours, 2 undifferentiated carcinoma tumours, together with 
38 metastatic lesions in the pelvic and peritoneal cavities) were obtained from the 
Department of Gynecology, the First Affiliated Hospital of China Medical University 
between 2004 and 2010. All patients were clinically staged according to the 
International Federation of Gynecology and Obstetrics (FIGO) system. The cases 
were selected based on the availability of the resection tissues, clinical follow-up data 
and no history of preoperative radiation or chemotherapy. Ages of the 114 patients 
ranged from 26 to 76 years (mean age, 53 years) and the average duration of 
follow-up was 45.2 months (range from 1 to 110 months). Two pathologists 
separately assessed the specimens to document primary tumour diagnosis as well as 
the presence of metastases in the pelvic and peritoneal cavity, tumours were 
pathologically graded according to the Silverberg grading system. The study was 
approved by the Medical Ethics Committee of the First Affiliated Hospital of China 
Medical University in accordance with the Helsinki Declaration. 
  
2.2   Cell lines 
Human EOC cell lines HO8910, CAOV3 and SKOV3-DDP were obtained from Cell 
Resource Center, Chinese Academy of Medical Sciences, Beijing. CAOV3 was 
cultured in DMEM with high glucose supplement (Sigma), HO8910 and SKOV3-DDP 
were cultured in RPMI 1640 (GIBCO). Both media were supplemented with 2mM 
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L-glutamine, penicillin-streptomycin (100U/ml) and 10% FBS and cells were cultured 
at the standard culture conditions. 
 
2.3   IL-33 siRNA transfection 
EOC cell lines were transfected with IL-33 or scramble siRNAs according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQ (OriGene Technologies, USA). Briefly cells were plated in 
6-well plates (3×105/well) and allowed to reach 50% confluence for transfection. 7.5µl 
of Lipofectamine 3000 (Life Technology) and 1µl of IL-33 or scramble siRNAs were 
separately pre-incubated in 125µl of Opti-MEM culture medium (Life Technology) for 
5mins. The two solutions were then mixed and incubated at room temperature for 
5mins. The mixture was then added to the cells pre-incubated in 1750µl of fresh 
culture medium. After 48h, the cells were harvested and transfection efficiency was 
evaluated using western blot analysis.  
 
2.4   Cell viability and proliferation assay 
Thiazolyl Blue Tetrazolium Bromide (MTT) assay is commonly used to measure cell 
metabolic activities, thus a composite readout of cell viability and proliferation. EOC 
cells in a 96-well plate (5×103/well) were starved of serum for 16h. Cells were then 
incubated in the absence or presence of 10ng/ml full length human IL-33 (fl-hIL-33, 
provided by Professor Mu, Peking University. Briefly, fl-Hil-33 was expressed in 
Escherichia Coli and purified by Ni-NTA affinity chromatogaraphy, endotoxin was 
removed and the levels were confirmed to be <0.1 unit/Pg of protein. The primary 
structure of fl-hIL-33 was confirmed by sequencing). 200ng/ml sST2 (R&D Systems), 
2µmol/L U0126 (Sigma) or 10µmol/L SP600125 (Sigma) for various time periods in 
different experiments. 20µl of MTT solution (5mg/ml in PBS, Sigma) was then added 
into each well and cells were incubated for a further 3h. The medium was removed 
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and 100Pl/well of dimethyl sulfoxide (DMSO) (Sigma) was added, the plate was 
gently rotated for 10mins before the absorbance was measured at 570nm.  
 
2.5   Wound healing assay 
EOC cells were seeded into six-well plates (3×105/well). When cells reached 70-80% 
confluence, complete medium was replaced with medium containing 1% FBS and 
cultured for a further 16h. The cultures were then scratched using a 200µl pipette tip 
across the cell monolayer and cells were gently washed with warm PBS and 
maintained in fresh 1% FBS medium with or without rhIL-33, sST2, U0126 and 
SP600125 as required in different experiments. Cell migration was photographed at 
0h and 48h. The area of the wound in each well was calculated using Image software.  
 
2.6   Transwell invasion assay 
EOC cell invasion was evaluated using a matrigel invasion chamber. Briefly, the cell 
inserts (Corning) were coated with 100Pl of matrigel (BD BioScience) and then placed 
in a 24-well plate. Cells (4×105/ml) suspended in 100Pl of medium containing 0.1% 
FBS with/without rhIL-33, sST2, U0126 or SP600125 were seeded in the top 
chambers. Dimethylsulfoxide (DMSO) was used to dissolve U0126 and SP600125 in 
our experiments, the final concentration of DMSO in the cell culture was 0.05% (v/v). 
The lower chambers were filled with 600Pl of medium containing 10% FBS. After 48h 
incubation, the inserts were removed and washed in PBS before being fixed and 
stained with hematoxylin. The non-invading cells together with the matrigel were 
removed and the cells migrating to the lower surfaces were examined and counted at 
a magnification of ×200 in five predetermined fields. Each experiment was carried out 
in triplicate.  
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2.7   Immunohistochemistry 
Formalin-fixed, paraffin-embedded EOC tissue sections (5Pm) were dewaxed and 
rehydrated before an antigen retrieval step. Sections were then incubated with 
anti-human primary antibodies for IL-33 (Enzo Life Sciences), ST2 (Sigma-Aldrich), 
Ki-67 (Abcam) or matching IgG isotypes overnight. Slides were then stained with 
species specific biotinylated secondary antibodies (R&D Corporation), 
streptavidin±HRP and detected with substrate AEC (3-amino-9-ethylcarbazole) 
(Vector Laboratories). After that, slides were counterstained with hematoxylin. The 
staining intensity was scored independently by two pathologists with strong staining 
marked as 2+, weak staining marked as 1+ and minimal staining as 0 [29, 30]. Three 
sections from each sample were examined.  
 
For EOC cell lines, cells were cultured on glass coverslips coated with poly-D-lysine 
(Sigma) with or without rhIL-33 in the culture medium for 48h. Cells were then fixed 
and incubated with anti-Ki-67 and other primary antibodies, and the subsequent 
staining steps were performed as described above. 
 
2.8   Protein extraction and western blot 
Total protein was harvested from cells and tissues, and protein concentrations were 
determined using Quick Start Bradford protein assay (Bio-Rad). Aliquots of samples 
were separated by SDS-PAGE and transferred to nitrocellulose membrane. 
Membranes were incubated with primary antibodies at 4 ºC overnight. Protein bands 
were detected by incubation with HRP-conjugated antibody (Pierce Biotechnology, 
USA) and visualized with Clarity Western ECL Substrate (Bio-Rad). Following 
antibodies used in the study were purchased from Cell Signaling Technology 
(Danvers, USA): ȕ-actin, NF-NB, phospho-NF-NB p65 (Ser536), p38, phospho-p38 
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(Thr180/Tyr182), SAPK/JNK, phospho-SAPK/JNK (Thr183/Tyr185), 
p44/42MAPK/ERK, and phospho-p44/42MAPK/ERK (Thr202/Tyr204).  
 
2.9   Statistical analysis 
Results are expressed as mean+SEM and the data are representative of at least 
three separate experiments. The Wilcoxon±Mann±Whitney test was used to 
determine the statistical differences of cell proliferation, migration and invasion 
between two samples. The comparison between protein expression levels in different 
groups (Fig 1C and Tables 1 and 2) was assessed using )LVKHU¶VH[DFWWHVW. Overall 
survival curves were generated using Kaplan±Meier method and compared using a 
log-rank test. P value <0.05 was regarded as statistically significant. 
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3.   Results 
3.1   The expression levels of IL-33 and ST2 are associated with metastasis 
and proliferation of EOC 
We first examined whether IL-33 and ST2 were expressed by normal ovary and 
ovarian tumour tissues using immunohistochemical staining, and the expression 
levels were then analyzed according to the established criteria for high-expression 
(staining 2+᧥and low-expression (staining 0 or 1+) (Gonzalez-Campora et al., 2011). 
Our data showed that IL-33 was undetectable in normal ovary tissues, and the 
expression levels were highly up-regulated in EOC samples with IL-33 positive 
staining localized to the cytoplasm as well as on the cell nucleus (Fig 1A). Similar to 
IL-33 expression, ST2 was not expressed by normal ovary tissues while high levels of 
ST2 positive staining were observed in EOC tissues with ST2 localized to the 
membrane and cytoplasm of cells (Fig 1B). Interestingly, when we compared the 
expression levels of IL-33 and ST2 in the tumours collected from the primary and 
metastatic sites, stronger staining of both IL-33 and ST2 was observed by the 
metastatic tumours, with additional nuclear staining of ST2 in the metastatic tumour 
cells but not primary tumour cells (Fig 1A and 1B).  
 
To understand whether there is a correlation between the expression levels of IL-33 
and ST2 and EOC metastasis, we screened the paraffin-embedded tissues of 20 
normal ovary, 20 benign tumours and 114 EOC samples. Our results (Table 1) show 
that all normal ovary tissues had low expression of IL-33 or ST2, with 10%-20% of 
ovary benign tumours had high expression levels of the molecules. However in EOC 
samples, there was a significant upregulation of IL-33 expression with 59% of primary 
site and 76% of metastatic EOC tumours had high levels of expression. The statistical 
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difference was more significant for ST2 expression as 87% of metastatic tumours had 
high ST2 expression compared to 66% of primary site tumours. Furthermore there 
was a significant correlation between the expression levels of IL-33 and ST2 in EOC 
and tumour metastasis. Using western blotting, we further assessed the difference of 
IL-33 and ST2 expression in paired primary site and metastatic site EOC tumours. 
Samples were collected at operative resection with each case being confirmed by 
pathology examination. Our data show (Fig 1C) that out of twelve patients, eight had 
increased expression of IL-33 in metastatic tumours compared with the primary 
tumours while nine out of twelve metastatic tumours had increased ST2 expression, 
the differences were statistically significant for both IL-DQG67XVLQJ)LVKHU¶VWHVW. 
Taken together our findings from both western blotting and immunohistochemical 
staining suggest that high levels of IL-33 and ST2 expression were closely correlated 
with EOC metastasis.  
 
3.2   The up-regulation of IL-33 and ST2 in EOC is an indicator of tumour cell 
proliferation and poor prognosis  
In addition to the tumour metastasis, we further analyzed whether there was a 
correlation between the expression levels of IL-33 and ST2 and patient age and other 
clinic pathological characteristics of EOC. Surprisingly, our data suggested that there 
was no significant correlation between the expression levels of IL-33 or ST2 and 
patient age, tumour histologic types, FIGO stages or differentiation (Table 2). 
However, IL-33 and ST2 expression levels were positively correlated with the 
expression of Ki-67 (Fig 2A, Table 2), further confirming a potential role of IL-33/ST2 
signaling axis in EOC growth and metastasis. To understand the clinical implications 
of the up-regulation of IL-33 and ST2, we collected and analyzed the clinical follow up 
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data of EOC patients. Our Kaplan-Meier patient overall survival analysis curves 
showed that higher expression level of IL-33 was closely correlated with reduced 
survival time for EOC patients (Fig 2B), and the correlation was even more significant 
with the expression level of ST2 (Fig 2C). Thus the data here show that IL-33/ST2 
axis plays an important role in ovarian cancer progression and are poor prognostic 
markers for patients. 
  
3.3   Knock down of IL-33 gene reduces the migratory and invasive potential 
of EOC cells   
The close correlation of IL-33/ST2 expression with EOC progression, particularly 
tumour metastasis suggests that IL-33/ST2 may be important in ovarian cancer cell 
growth, migration and invasion. We studied the role of IL-33 in EOC cell behaviour 
using cell lines. First we examined the expression of IL-33 and ST2 by EOC cell lines 
CAOV3, HO8910 and SKOV3-DDP. In agreement with our staining data of EOC 
patient tumour tissues, both IL-33 and ST2 were highly expressed by all three cell 
lines as confirmed by both immunohistochecmial staining (data not shown) and 
western blot (Fig 3A). Next, we disrupted IL-33 gene expression in the cell lines using 
siRNA, and tested the effect of endogenous IL-33 on EOC cell function. After 
transfection of IL-33 specific siRNA, the expression of IL-33 was dramatically 
decreased in all three cell lines as expected (Fig 3B) when compared with scramble 
control cells. Furthermore, cell viability, migration and invasion assays were 
performed to evaluate the role of IL-33 in EOC cell behaviour. While IL-33 
knock-down had no effect on cell viability/proliferation in all three cell lines (data not 
shown), the cells transfected with IL-33 siRNA had significantly reduced their 
migration (Fig 4A) and invasion capacity (Fig 4B) as tested by the wound healing and 
transwell invasion assays.  
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3.4   Fl-hIL-33 increases the migratory, invasive and proliferative potential of 
EOC cells  
To understand the function of IL-33/ST2 in EOC development, we investigated the 
effect of exogenous IL-33 on cell metabolic activity, invasion and migration using 
CAOV3 and HO8910 cell lines. Cells were first incubated with or without 200ng/ml 
sST2 for 3h before adding 10ng/ml of fl-hIL-33 in the culture for a further 48h. As 
shown in Figure 4, fl-hIL-33 not only increased the cell migration (Fig 5A) and 
invasion (Fig 5B), but also enhanced the cell viability/proliferation of both cell lines 
(Fig 5C). Furthermore, the staining of Ki-67 protein was also elevated in the cells 
treated with fl-hIL-33 (Fig 5D). While the administration of IL-33 decoy receptor sST2 
was able to block the stimulatory effect of fl-hIL-33 on EOC cell migration, invasion 
and proliferation, sST2 also decreased IL-33-induced up-regulation of Ki-67 in EOC 
cells (Fig 5). 
 
3.5   Fl-hIL-33 increases ovarian cancer migration, invasion and proliferation 
through ERK and JNK pathways 
Numerous signaling pathways are involved in the aggressive behaviour of cancer 
cells, unraveling these signaling networks will provide important insights into cancer 
development. To understand the molecular mechanisms of IL-33/ST2 effect on 
ovarian cell growth and metastasis, we next investigated the changes in the signaling 
pathways of EOC cells after treatment with fl-hIL-33. We observed an obvious 
increase in the phosphorylation of JNK and ERK with a peak of phosphorylation 
occurring at 10mins after fl-hIL-33 stimulation, but no change was observed with 
NF-NB and p38 (Fig 6A). Phosphorylation of ERK and JNK was completely blocked 
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by sST2 (Fig 6B). We further demonstrated that U0126 (2wmol/l), an inhibitor of 
MAPK/ERK, significantly inhibited the phosphorylation of ERK in CAOV3 and 
HO8910 cells (Fig 7A). It also blocked the IL-33 mediated increase of cell migratory 
(Fig 7C) and invasive (Fig 7D) potential, together with cell viability/proliferation in 
CAOV3 cells (Fig 7E). When the JNK pathway inhibitor SP600125 (10wmol/l) was 
added to the cells, it inhibited JNK phosphorylation in CAOV3 and HO8910 cells as 
expected (Fig 7B). Surprisingly SP600125 had no effect on the IL-33-induced 
increase in cell migratory (Fig 7C) and invasive (Fig 7D) potential, and was only able 
to disrupt IL-33-induced enhancement of cell viability/proliferation (Fig 7E) of CAOV3 
cells. DMSO was used to dissolve SP600125 and U0126 and our control experiments 
confirmed that low concentrations of DMSO used in the study had no effect on EOC 
cell behavior and the phosphorylation of JNK and ERK (Supplementary Fig 1). 
Collectively, our data demonstrate that the different roles of IL-33/ST2 in ovarian 
cancer cell growth, migration and invasion are mediated by complex signaling 
pathways.  
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4.   Discussion 
New evidence suggests that IL-33/ST2 axis is likely to play a role in cancer 
development and progression (Milovanovic et al., 2012), however its exact function in 
ovarian cancer growth and metastasis has not been defined. To our knowledge, our 
study is the first to demonstrate that the expression levels of both IL-33 and ST2 in 
EOC tumours are closely correlated with tumour metastasis and patient prognosis, 
and IL-33/ST2 axis contributes to EOC progression through mechanisms of 
promoting cancer cell growth and migration. 
 
Several recent studies suggest that serum levels of IL-33 (Sun et al., 2011; Hu et al., 
2013) and sST2 (Bergis et al., 2013; Lu et al., 2014) correlate with clinical prognosis 
of patients in various malignancies. In this study we have demonstrated that IL-33 
and ST2 are highly elevated in EOC tumours compared with normal and benign 
tumour ovary tissues, and the levels are significantly increased in the tumours at the 
metastatic sites compared with the primary site tumours. These data suggest the 
IL-33/ST2 signaling pathway is very likely to be involved in the development of 
advanced EOC. Indeed, analysis of our clinical follow up records of a large cohort of 
EOC patients for nearly 10 years reveals that high levels of IL-33 and ST2 expression 
in EOC tissues are closely correlated with reduced survival rates of patients, 
indicating that IL-33 and ST2 are poor prognosis markers for EOC patients. Thus our 
data add to the current knowledge that IL-33/ST2 are potential prognostic markers for 
some malignant cancers.    
 
Although emerging evidence strongly supports a role for IL-33/ST2 in cancer 
development, the precise underlying mechanism through which IL-33 facilitates 
cancer cell growth and metastasis is unclear. Our study suggests that IL-33, highly 
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elevated in EOC tumour tissues, is able to modulate the behaviour of cancer cells 
directly. It facilitates EOC progression and metastasis through promoting tumour cell 
invasion, migration and proliferation. While sST2 is able to block the function of IL-33 
in enhancing EOC cell migration, invasion and cell viability, IL-33 gene disruption 
using siRNA reduces the cell migration and invasion but not the cell viability. The 
further up-regulation of IL-33 and ST2 by the metastatic EOC tumours indicates that 
IL-33 might act in an autocrine feedback mechanism to promote EOC progression 
and enhance the aggressive behaviour of EOC cells. Indeed as IL-33 is also 
regarded as an alarmin molecule and an important immunoregulatory cytokine (Pei et 
al., 2014), it might be argued that IL-33 is released by cancer cells into the tumour 
microenvironment where it binds to its receptor ST2 expressed on cancer cells and 
the infiltrating immune cells. As inflammation, immunity and cancer development are 
intimately related, it is highly likely that IL-33 might be one of the key molecules 
employed by cancer cells to promote cancer development through directly modifying 
cancer cell behaviour and indirectly modulating the infiltrating immune cells, thus 
linking the communications between these cells in an autocrine and/or paracrine 
feedback mechanism to promote cancer progression.   
 
A few studies have examined the role of IL-33 in anti-tumour immune responses 
during cancer development (Gao et al., 2013; Jovanovic et al., 2011; Milovanovic et 
al., 2012) however with contradictory results. One study suggested that IL-33 acted 
as a crucial mediator in inflammation-associated pancreatic carcinogenesis by 
up-regulating secretion of the pro-inflammatory IL-6 and IL-8 cytokines (Schmieder et 
al., 2012). Transgenic IL-33 was shown to be able to activate NK and CD8 T cells and 
inhibited tumour growth and metastasis in melanoma and lung carcinoma animal 
models (Gao K, et al., 2013; Gao X, et al., 2015). Other reports showed that IL-33 
20 
 
enhanced type-2 immune responses (Barbour et al., 2014; Besnard et al., 2011; 
Kurowska-Stolarska et al., 2009; Jiang et al., 2012; Miller et al., 2008;) and thus 
suppressed activities of NK cells and accelerated cancer progression in tumour 
bearing animals (Jovanovic et al., 2014; Solinas et al., 2009). The reason for the 
discrepancy is not known, the data may reflect the different microenvironment in 
different cancer development and IL-33 may have specific anti-tumour immune 
responses in different cancer. Chronic inflammation underlies the progression 
of ovarian cancer (Lavoue et al., 2013), whether IL-33 influences the development of 
EOC through modulating the immune system is currently unknown and awaits further 
investigation.   
 
Apart from the immune cells, cancer cells also have constant communications with 
other surrounding cells in the tumour microenvironment. Indeed, IL-33 promotes the 
invasiveness of head and neck squamous cell carcinoma through mediating the 
invasiveness of the key tumour-surrounding carcinoma-associated fibroblasts (Chen 
et al., 2013), suggesting IL-33 is one of the key mediators between cancer and 
stromal cells. As IL-33 also induces angiogenesis and vasopermeability (Choi et al., 
2009), a study in squamous cell carcinoma of the tongue suggested that IL-33 
influences the malignant potential of the tumour through the promotion of 
angiogenesis in the tumour microenvironment (Ishikawa et al., 2014). In our 
immunohistochemical staining data, we observed that IL-33 and ST2 were highly 
expressed by cancer cells and also the surrounding stromal cells, suggesting there 
might be a close interaction between the EOC and stromal cells.  
 
IL-33 binds to ST2 and activates the downstream signaling pathways through NF-NB 
as well as MAPKs pathways (Liew, 2012), key signaling pathways for cancer cell 
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activities such as proliferation, migration and invasion. Current evidence indicates 
that gene- and cell-specific differences often exist in IL-33 activated signaling 
pathways (Milovanovic et al., 2012; Zhou et al., 2014). NF-NB is a key player in innate 
immunity and inflammation, and the IL-33 effect on cytokine production appeared to 
be mediated via NF-NB activation as shown in pancreatic carcinoma cells (Schmieder 
et al., 2012). Other studies show that P38 signaling pathway was associated with the 
pro-melanogenic activity of IL-33 in primary melonocytes (Zhou et al., 2014), while 
IL-33 enhanced proliferation and invasiveness of decidual stromal cells were 
mediated via both NF-NB and ERK1/2 signaling (Hu et al., 2014). To understand the 
molecular mechanisms underlying the function of IL-33 in EOC cell proliferation, 
migration and invasion, we examined the phosphorylation of multiple MAPKs, 
including ERK1/2, JNK and p38 as well as NF-NB in the EOC cell lines. Our results 
identified important roles for the ERK and JNK signaling pathways in IL-33 mediated 
aggressive behaviour of EOC cells as there was dramatic increase in the 
phosphorylation of ERK and JNK after fl-hIL-33 stimulation, and the increase was 
blocked by IL-33 decoy receptor sST2. However, neither NF-NB or p38 
phosphorylation was detected, suggesting they were not involved in IL-33 mediated 
EOC cell metastasis and proliferation. We further demonstrated that the ERK 
pathway is specifically associated with IL-33-mediated increases in the invasive, 
migratory and proliferative potential of EOC cells, but the JNK pathway was only 
involved in IL-33-mediated increases in proliferation using ERK and JNK specific 
inhibitors. Therefore, specific function of fl-hIL-33 in different cells is likely to be 
regulated through distinct signaling pathways, while it increased EOC cell invasion 
and migration through the ERK pathways, but it promoted cell proliferation through 
both the ERK and JNK pathways.   
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In conclusion, we demonstrate that high levels of IL-33 and ST2 are expressed by 
EOC tumours, particularly those at the metastatic sites. We also show that the 
expression levels of both molecules are significantly correlated with poor prognosis of 
patient survival time. IL-33 facilitates ovarian cancer progression by promoting EOC 
cell proliferation, migration and through ERK and JNK specific pathways. The 
information obtained from our study provides an important insight into the 
mechanisms of metastases in EOC. Our data indicate that IL-33 and ST2 are 
potential prognostic markers as well as possible therapeutic targets for clinical 
intervention for EOC and other cancer patients. 
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Legends: 
Fig 1. Expression levels of IL-33 and ST2 are up-regulated in EOC tumours 
compared with normal ovary tissues. (A) Representative immunohistochemical 
staining of IL-33 in normal ovary, EOC tumours at primary site and metastatic site at 
100× and 400× original magnification. (B) Representative immunohistochemical 
staining of ST2 in normal ovary, EOC primary site and metastatic site. Arrows 
indicate tumour cells in the tissue. (C) Western blots of IL-33 and ST2 in patient 
primary site tumours (P) compared with metastases (M). Fisher¶s exact test was used 
to analyze the statistical difference for IL-33 and ST2 expression between primary 
and metastatic site EOC tumous, both P<0.05. 
 
Fig 2. Correlation of IL-33/ST2 expression with patient survival time. (A) Expression 
of Ki-67 at EOC tumours at 100× and 400× original magnification. (B) Kaplan-Meier 
patient overall survival analysis curves for 114 EOC patients with high (2+) or low (0 
or 1+) expression of IL-33. (C) Kaplan-Meier patient overall survival analysis curves 
for EOC patients with high (2+) or low (0 or 1+) expression of ST2. The follow up 
period was 45.2 months (range, from 1 to 110 months).  
 
Fig 3. IL-33 and ST2 expression by EOC cell lines and knockdown of IL-33 gene by 
siRNA. (A) Western blot examined the expression of IL-33 and ST2 by CAOV3, 
HO8910 and SKOV3-DDP cell lines; (B) After transfection of IL-33 siRNA1, siRNA2 
or scramble control siRNA, the expression of IL-33 was examined in all three cell 
lines by western blot.   
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Fig 4. Knock down of IL-33 gene reduces the invasive and migratory potential of EOC 
cell lines. Cell lines transfected with IL-33 specific siRNAs or scamble control siRNA 
were examined for cell migration (A) and invasive capacity (B) using wound healing 
and transwell invasion assays respectively. Data were expressed as mean+SEM, * P 
< 0.05. Results are representative of 3 different experiments.  
 
Fig 5. Fl-hIL-33 promotes the invasive and migratory potential of EOC cells and 
increased cell proliferation. CAOV3 and HO8910 cells were treated with or without 
fl-hIL-33 (10ng/ml), in some wells cells were pre-incubated with sST2 (200ng/ml) for 
3h before adding fl-hIL-33. The effect of IL-33 on cell migration (A), invasion (B) and 
cell viability (C) was tested using wound healing, transwell invasion and MTT assays 
respectively. (D) Immunohistochemical staining of the cells with Ki-67 antibody. Data 
in A, B, and C were expressed as mean+SEM ZLWK WKH FRQWURO DV ³00%´ LQ FHOO
viability assay. * P < 0.05. Results are representative of 3 different experiments. 
 
Fig 6. Fl-hIL-33 increases the phosphorylation of ERK and JNK and this was blocked 
by sST2. (A) CAOV3 and HO8910 cells were stimulated with fl-hIL-33 (10ng/ml) for 
the indicated times (0, 10, 30, 60, 120mins) and then harvested for western blot 
assay of P-NF-NB, NF-NB, P-JNK, JNK, P-P38, P38, P-ERK1/2, ERK1/2 and ˟-actin. 
(B) CAOV3 and HO8910 cells were pretreated with 200ng/ml sST2 for 3h before 
adding rhIL-33 (10ng/ml) for 10mins. Cells were then harvested and examined for the 
expression of phosphorylation of MAPKs JNK and ERK.  
 
Fig 7. The effect of fl-hIL-33 on EOC cell invasion, migration and proliferation was 
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specifically mediated by the ERK and the JNK pathways. CAOV3 and HO8910 cells 
were pre-treated with 2µmol/ml U0126 (inhibitor of ERK) and 10µmol/ml SP600125 
(inhibitor of JNK) for 30mins before being incubated with rh-IL-33 (10ng/ml) for 
10mins. Phosphorylation of ERK (A) and JNK (B) was evaluated by western blot. 
(C-E) CAOV3 cells were pre-treated with U0126 or SP600125 before adding rhIL-33, 
and then used to study the migratory (C), invasive (D) potential and cell viability (E). 
Data are expressed as mean+6(0ZLWKWKHFRQWURODV³00%´LQFHOOYLDELOLW\DVVD\
P < 0.05. Results are representative of 3 different experiments. 
 
Supplementary Fig 1. The effect of low level of DMSO on EOC cell behaviour and 
phosphorylation. CAOV3 cells were treated with or without 0.05% DMSO in the 
culture and its effects on cell invasion (A), migration (B) and cell viability/proliferation 
(C) were tested using the methods described in the manuscript. (D) CAOV3 and 
HO8910 cells were cultured with or without 0.05% DMSO, and then cells were 
harvested and examined for the expression of phosphorylation of JNK and ERK by 
western blot.  
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Table 1. IL-33 and ST2 expression in normal ovary, benign ovarian tumour and EOC tissues 
 
Groups n No. of Patients (%)       
IL-33 protein expression 
0 or 1+      2+ 
No. of Patients (%)       
ST2 protein expression 
0 or 1+        2+ 
Normal ovary 20 20 (100)      0 (0)      20 (100)         0 (0) 
Benign 
tumours 
20 18 (90)       2 (10) 16 (80)          4 (20)     
EOC 
Primary 
metastasis 
 
114 
38 
 
47 (41)      67 (59)* 
9 (24)       29 (76)
%
 
 
39 (34)         75 (66)* 
5 (13)          33 (87)
#
   
 
* Expression levels of IL-33 or ST2 were compared between normal ovary and ovarian 
benign tumours, P < 0.01; 
%
 comparison of expression levels of IL-33 between primary site 
and metastatic site tumours, P < 0.05; 
#
 comparison of expression levels of ST2 between 
primary site and metastatic site EOC, P < 0.01. W ǀĂůƵĞƐ ǁĞƌĞ ĐĂůĐƵůĂƚĞĚ ďǇ &ŝƐŚĞƌ ?Ɛ ĞǆĂĐƚ
test. 
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Table 2. Correlation of IL-33 and ST2 expression with clinicopathological features of EOC 
 
Characteristic n No. of Patients (%) 
IL-33 expression   P Value 
0 or 1+   2+ 
No. of Patients (%) 
ST2 expression    P Value 
0 or 1+  2+ 
Age (years) 
>60 
ч ? ? 
 
51 
63 
                0.774 
22(43)   29(57)            
25(40)   38(60) 
               0.881 
17(33)   34(67) 
22(35)   41(65) 
Histologic type 
Serous carcinoma 
Mucinous carcinoma 
and others 
 
88 
 
26 
                0.155                           
34(39)   54(61) 
        
13(50)   13(50) 
                0.187 
28(32)   60(68) 
 
11(42)   15(58) 
FIGO disease stage 
I-II 
III-IV 
 
28 
86 
                0.117                              
14(50)   14(50) 
33(38)   53(62) 
                0.107 
12(43)   16(57) 
27(31)   59(69) 
Differentiation 
Well and moderate 
Poor 
 
70 
44 
                0.112                             
32(46)   38(54) 
15(34)   29(66) 
                0.098 
27(39)   43(59) 
12(27)   32(73) 
Ki-67 expression 
0 or 1+ 
2+ 
 
47 
67 
                0.006                             
25(53)   22(47) 
22(33)   45(67) 
                0.002 
22(47)   25(53) 
17(25)   50(75) 
 
P values were calculated by &ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚ ? 
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